Cibus, Inc. (CBUS) Form 8-K — Aug 13, 2026
Cibus reported a second-quarter 2026 net loss of $22.1 million ($0.29 per Class A share), narrowed from $26.6 million ($0.61) a year earlier, on revenue of $994,000 versus $933,000 in the year-ago quarter. Cost reductions cut R&D expense to $8.5 million from $12.2 million and SG&A to $5.4 million from $6.6 million year over year. The company ended the quarter with $20.4 million in cash and said that, absent new financing, existing cash is sufficient to fund operations into early in the first quarter of 2027. Cibus expects an annual net cash usage run-rate of approximately $35 million exiting 2026, with quarterly net cash usage down roughly 19% sequentially and 31% year over year.
Key figures
- Revenue
- 994000
- Guidance
- Expects annual net cash usage run-rate of approximately $35 million exiting 2026; existing cash and cash equivalents sufficient to fund planned operating expenses and capital expenditures into early in the first quarter of 2027, before any potential financing transactions.
- Revenue Yoy
- +6.5% (Q2 2026 $994K vs Q2 2025 $933K)
- Total Assets
- 313447000
- Cash Position
- 20429000
- Shares Outstanding
- 76423033
- Cash runway
- into early in the first quarter of 2027
- Goodwill usd
- 232516000
- Q2 2025 rnd expense usd
- 12228000
- Q2 2025 sga expense usd
- 6651000
- Q2 2026 rnd expense usd
- 8506000
- Q2 2026 sga expense usd
- 5413000
- Stockholders equity usd
- 14802000
- Six month 2025 revenue usd
- 1967000
- Six month 2026 revenue usd
- 2675000
- Rice peak addressable acres
- 5-7 million
- Shares outstanding dec 31 2025
- 54325852
- Quarterly net cash usage yoy decline
- approximately 31%
- Royalty liability related parties usd
- 253519000
- Quarterly net cash usage sequential decline
- approximately 19%
- Royalty liability interest expense q2 2026 usd
- 9475000
- Net cash used in operations six months 2025 usd
- 25431000
- Net cash used in operations six months 2026 usd
- 20894000
- Rice annual addressable royalty opportunity usd
- approximately $200 million
- Biofragrance peak annual revenue opportunity usd
- $20-$40 million
- Proceeds from securities issuances six months 2026 usd
- 37260000
Price after filing
Close on the filing date to close N calendar days later (from $1.90). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.